AR ligand-2 | 956902-17-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: AR ligand-2
• 英文别名: 4-(2-Hydroxyphenyl)-2-(trifluoromethyl)benzonitrile
• CAS: 956902-17-3
• 化学式: C₁₄H₈F₃NO
• 分子量: 263.219
• InChiKey: CSOANLOTNWGJSK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  44
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  AR ligand-2 、 1-溴-2-(2-甲氧基乙氧基)乙烷 在 potassium carbonate 作用下， 以 丙酮 为溶剂， 反应 5.0h， 生成 2''-[2-(2-Methoxy-ethoxy)-ethoxy]-3-trifluoromethyl-biphenyl-4-carbonitrile
  参考文献：
  名称：

  Preparation of 4-aryl-2-trifluoromethylbenzonitrile derivatives as androgen receptor antagonists for topical suppression of sebum production

  摘要：

  A series of substituted 4-aryl-2-trifluoromethylbenzonitrile analogs were evaluated in the human androgen receptor binding and cellular functional assays. Analogs with sufficient in vitro binding and cellular potency (IC50 < 200 nM) were tested in the progesterone receptor binding assay for selectivity and in the Golden Syrian hamster ear model for in vivo efficacy. Within the series, compound 4e was identified to be the most active analog in vivo (wax ester inhibition = 86%). (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.08.034
• 作为产物：
  描述：

  2-氰基-5-碘三氟甲苯 、 2-羟基苯硼酸 在 四(三苯基膦)钯 potassium carbonate 作用下， 以 乙二醇二甲醚 、 水 为溶剂， 反应 18.0h， 生成 AR ligand-2
  参考文献：
  名称：

  Preparation of 4-aryl-2-trifluoromethylbenzonitrile derivatives as androgen receptor antagonists for topical suppression of sebum production

  摘要：

  A series of substituted 4-aryl-2-trifluoromethylbenzonitrile analogs were evaluated in the human androgen receptor binding and cellular functional assays. Analogs with sufficient in vitro binding and cellular potency (IC50 < 200 nM) were tested in the progesterone receptor binding assay for selectivity and in the Golden Syrian hamster ear model for in vivo efficacy. Within the series, compound 4e was identified to be the most active analog in vivo (wax ester inhibition = 86%). (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.08.034

文献信息

• Novel Bicyclic Pyridinones
  申请人：Pettersson Martin Youngjin

  公开号：US20120252758A1

  公开（公告）日：2012-10-04

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I as defined herein. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  所述化合物及其药用可接受的盐被披露，其中所述化合物具有如本文所定义的Formula I的结构。相应的药物组合物、治疗方法、合成方法和中间体也被披露。
• NOVEL BICYCLIC PYRIDINONES
  申请人：Pfizer Inc.

  公开号：EP2691393A1

  公开（公告）日：2014-02-05
• US8697673B2
  申请人：——

  公开号：US8697673B2

  公开（公告）日：2014-04-15
• US9067934B2
  申请人：——

  公开号：US9067934B2

  公开（公告）日：2015-06-30
• [EN] NOVEL BICYCLIC PYRIDINONES<br/>[FR] NOUVELLES PYRIDONES BICYCLIQUES
  申请人：PFIZER

  公开号：WO2012131539A1

  公开（公告）日：2012-10-04

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I) as defined herein. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.